SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr. Reddy’s Laboratories gains on launching Bupropion HCI Tablets in US market

06 Sep 2016 Evaluate

Dr. Reddy’s Laboratories is currently trading at Rs. 3137.05, up by 14.40 points or 0.46% from its previous closing of Rs. 3122.65 on the BSE.

The scrip opened at Rs. 3123.00 and has touched a high and low of Rs. 3142.85 and Rs. 3123.00 respectively.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 4382.95 on 20-Oct-2015 and a 52 week low of Rs. 2750.00 on 21-Jan-2016.

Last one week high and low of the scrip stood at Rs. 3142.85 and Rs. 3019.00 respectively. The current market cap of the company is Rs. 51,959.00 crore.

The promoters holding in the company stood at 26.37%, while Institutions and Non-Institutions held 41.16% and 15.64% respectively.

Dr. Reddy’s Laboratories has launched Bupropion HCI extended-release tablets, USP (SR) in 100 mg, 150 mg and 200 mg, a therapeutic equivalent generic version of Wellbutrin SR (bupropion HCI) Sustained-Release Tablets in the United States market approved by the US Food & Drug Administration (USFDA). Dr. Reddy’s Buproprion SR tablets are available in 100 mg, 150 mg and 200 mg, in bottle count sizes of 60, 100 and 500.

Wellbutrin SR is a registered trademark of the GSK group of companies. The Wellbutrin SR brand and generic had US sales of approximately $109.6 million MAT for the most recent twelve months ending in July 2016, according to IMS Health.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It is committed to provide affordable and innovative medicines for healthier lives.  It manufactures and markets a wide range of pharmaceuticals in India and overseas.


Dr. Reddys Lab Share Price

1293.25 -13.55 (-1.04%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×